Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Syndax Pharmaceuticals (SNDX) Non Operating Income (2016 - 2020)

Syndax Pharmaceuticals has reported Non Operating Income over the past 6 years, most recently at -$563000.0 for Q4 2020.

  • Quarterly results put Non Operating Income at -$563000.0 for Q4 2020, down 374.63% from a year ago — trailing twelve months through Dec 2020 was -$1.7 million (down 216.29% YoY), and the annual figure for FY2025 was -$12.3 million, down 158.99%.
  • Non Operating Income for Q4 2020 was -$563000.0 at Syndax Pharmaceuticals, up from -$584000.0 in the prior quarter.
  • Over the last five years, Non Operating Income for SNDX hit a ceiling of $563000.0 in Q2 2018 and a floor of -$1.6 million in Q1 2016.
  • Median Non Operating Income over the past 5 years was $298000.0 (2016), compared with a mean of $105900.0.
  • Biggest five-year swings in Non Operating Income: surged 177.34% in 2018 and later plummeted 374.63% in 2020.
  • Syndax Pharmaceuticals' Non Operating Income stood at $326000.0 in 2016, then increased by 18.1% to $385000.0 in 2017, then increased by 28.83% to $496000.0 in 2018, then tumbled by 58.67% to $205000.0 in 2019, then plummeted by 374.63% to -$563000.0 in 2020.
  • The last three reported values for Non Operating Income were -$563000.0 (Q4 2020), -$584000.0 (Q3 2020), and -$452000.0 (Q2 2020) per Business Quant data.